Lateral ridge augmentation using particulated or block bone substitutes biocoated with rhGDF-5 and rhBMP-2: an immunohistochemical study in dogs.
OBJECTIVE
The aim of the present study was to immunohistochemically evaluate lateral ridge augmentation using a particulated (BOG) or block (BOB) natural bone mineral biocoated with rhGDF-5 and rhBMP-2 in dogs.


METHODS
Three standardized box-shaped defects were surgically created at the buccal aspect of the alveolar ridge in each quadrant of eight beagle dogs. After 2 months of healing, the chronic-type defects were randomly allocated in a split-mouth design to either (i) BOG or (ii) BOB biocoated with (a) rhGDF-5 or (b) rhBMP-2, respectively. Uncoated grafts served as controls. After 3 and 8 weeks, dissected blocks were prepared for immunohistochemical [osteocalcin (OC)] and histomorphometrical analysis [e.g. area (mm(2)) of new bone fill (BF), newly formed mineralized (MT) and non-mineralized tissue (NMT)].


RESULTS
rhBMP-2 biocoated BOG revealed significantly highest BF and MT values at 3 (upper and lower jaws - UJ/LJ - compared with BOG) and 8 weeks (UJ - compared with rhGDF-5). Biocoating of BOB using both rhGDF-5 and rhBMP-2 resulted in significantly increased MT values at 8 weeks (UJ/LJ - compared with BOB). In all groups, NMT adjacent to BOG and BOB scaffolds revealed pronounced signs of an OC antigen reactivity.


CONCLUSIONS
Within the limits of the present study, it was concluded that both rhGDF-5 and rhBMP-2 have shown efficacy; however, their bone regenerative effect was markedly influenced by the carrier.
Schwarz
Frank
F
Department of Oral Surgery, Heinrich Heine University, Düsseldorf, Germany. Frank.Schwarz@med.uni-duesseldorf.de
Rothamel
Daniel
D
Herten
Monika
M
Ferrari
Daniel
D
Sager
Martin
M
Becker
Jürgen
J
D000540:Alveolar Ridge Augmentation / Q000379:methods*; D000818:Animals; D001857:Bone Matrix / Q000637:transplantation*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D018786:Bone Substitutes; D016025:Bone Transplantation / Q000379:methods; D020099:Coated Materials, Biocompatible; D004285:Dogs; D055428:Growth Differentiation Factor 5; D016557:Guided Tissue Regeneration, Periodontal; D006801:Humans; D007124:Immunoenzyme Techniques; D008903:Minerals; D015675:Osteocalcin / Q000096:biosynthesis; D011897:Random Allocation; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
C525718:BMP2 protein, human; C077540:Bio-Oss; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D020099:Coated Materials, Biocompatible; C525893:GDF5 protein, human; D055428:Growth Differentiation Factor 5; D008903:Minerals; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D015675:Osteocalcin